Navigation Links
TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
Date:3/12/2010

TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a novel non-fluorinated quinolone that has a broad spectrum of activity against gram-positive and gram-negative bacteria and atypical pathogens. Importantly, nemonoxacin possesses activities against Methicillin-Resistant Staphylococcus aureus (MRSA) and vancomycin-resistant pathogens. This single arm, proof-of-concept study was conducted in US, South Africa, Thailand and Taiwan in mild to moderate DFI patients who were treated with nemonoxacin 750mg once daily for one or two weeks. Nemonoxacin showed higher clinical and microbiology success rates compared with previous DFI trials. Among the 40 enrolled patients, there were four MRSA-infected patients, including one patient with quinolone-resistant MRSA, who were clinically successful treated. Nemonoxacin also demonstrated excellent pharmacokinetic profile in tissue penetration and relatively low drug-drug interactions in this group of patients who received multiple medications concomitantly for other disease conditions.

"In addition to the top-line efficacy and safety data from our early phase 2 Community-Acquired Pneumonia (CAP) trial, we are very encouraged by the DFI data. With the clinically proven superior anti-MRSA activity and efficacy in DFI patients - a very difficult-to-treat patient population, we believe nemonoxacin is not only the best in class quinolone drug, but also the first in class anti-MRSA quinolone drug with excellent safety profile. Increasing prevalence of Community-acquired MRSA infection has become a highly unmet medical need with limited alternative treatment options. Nemonoxacin represents a promise to the cure that TaiGen will deliver with great hope," commented Dr. Ming-Chu Hsu, Chairman & CEO of TaiGen.

About TaiGen Biotechnology

TaiGen Biotechnology (http://www.taigenbiotech.com/ ) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company has a full capacity in discovery research and clinical development in China/Taiwan/US. Its current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market. Nemonoxacin, a novel broad-spectrum non-fluorinated quinolone with anti-MRSA activity and in-licensed from P&G Pharmaceuticals, achieved non-inferiority in clinical cure rate and safety profile compared with Levofloxacin in its Phase II CAP trial. TaiGen is seeking Nemonoxacin licensees for the US, EU and Japan markets.

    TaiGen Contact
     Dr. John Jin
     VP Global Business Development
     Tel:     +886-2-2790-1861
     Email:   johnjin@taigenbiotech.com.tw

SOURCE TaiGen Biotechnology Co., Ltd.

Back to top

RELATED LINKS
http://www.taigenbiotech.com/

'/>"/>

SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for fiscal management and accountability, ... premier online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in ... by Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth ...
(Date:6/23/2017)... NY (PRWEB) , ... June 23, 2017 , ... ... certified plastic surgeon practicing in Newburgh, New York, has recently begun offering three ... Committed to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is ...
(Date:6/23/2017)... ... 23, 2017 , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s ... with a proprietary technique that he calls the AuraLyft Facelift. The AuraLyft ... ages, patients can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... Now’s 28th facility overall and marks the urgent care center's eighth location in Miami-Dade ... of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting ... pm to present to graduate students exciting new and innovative hope research based on ... by The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) ...
Breaking Medicine News(10 mins):